Home CBD Classics UK on the Verge of Approving CBD-Based Drug for Dementia

UK on the Verge of Approving CBD-Based Drug for Dementia

103
0
SHARE

The widespread popularity of CBD is increasing on a daily basis. Almost every day there is a new story of diseases that CBD can treat. However, health officials have expressed caution, warning customers to be cautious about these claims.

Cannabidiol or CBD is a chemical compound extracted from the Cannabis plant. This chemical compound has been widely tested and studied by scientists. The results of these studies are revealing because they prove that CBD has numerous medical benefits. However, people on the Internet get carried away and spread unsubstantial claims about diseases that CBD can cure.

The Food and Drug Administration (FDA) has only approved one CBD-based drug meant for the treatment of epilepsy. Epientouragediolex is the name of the first CBD-based drug approved in the US. This drug is said to reduced seizures in two rare forms of epilepsy that usually affects children.

The US is not the only western country looking to CBD for treatment. In the United Kingdom, health officials may soon approve a new cannabis-based drug for the treatment of dementia. Reports say, researchers at King’s College London are conducting a study into a CBD-based drug that could treat the symptoms of dementia.

Sativex is named of the new cannabis-based drug, and researchers have recently launched a Phase 2 trial for it. Sativex has already been approved in the UK for the treatment of muscle stiffness and tightness that people with multiple sclerosis suffer from. Researchers are studying to see how Sativex can treat agitation in people who have Alzheimer’s disease.

Alzheimer’s Research UK funds the research into using Sativex to treat agitation in patients of Alzheimer’s disease. This charity organization focuses on dementia research.

Sativex is a cannabis-based drug that contains CBD and THC or Tetrahydrocannabinol. Sativex also contains peppermint and the CBD and THC in it are of equal proportions. Sativex is described as a mouth spray.

Researchers are hoping that there will be a breakthrough with Sativex since there are very few medications for Alzheimer’s disease. Memantine is the last medication that was approved from Alzheimer’s in Europe in 2002. The US supported Memantine in 2003.

One of the common symptoms of Alzheimer’s is memory loss. However, aggression and agitation are also other symptoms that pose challenges for Alzheimer’s patients and their caregivers.

“Current treatment for behavioral and psychiatric symptoms of dementia are very limited, and we desperately need to develop alternatives,” Dag Aarsland, the leader of the study into Sativex, said.

Researchers are studying into the efficacy of Sativex (a mouth wash) and how it can help aggression and agitation in patients with Alzheimer’s. Researchers are looking to recruit volunteers with aggression and agitation with Alzheimer’s.

“With no new dementia treatments in over 15 years, it is vital that we test a wide range of approaches to find effective ways to help people living with the condition,” said David Reynolds, the chief scientific officer at Alzheimer’s Research UK.